Parkinson’s Disease and Schizophrenia Flashcards
What are the three main dopaminergic pathways in the brain?
Nigrostriatal
Mesolimbic
Mesocortical
Where are the three main dopaminergic pathways in the brain found?
Nigrostriatal– projecting from the substantia nigra pars compacta to the striatum
Mesolimbic– ventral tegmental area (VTA) to the Nucleus Accumbens (NAcc)
Tuburoinfundibular system– VTA to the cerebrum.
What are the roles of the three main dopaminergic pathways in the brain?
Nigrostriatal – control of movement
Mesolimbic – involved in emotion
Mesocortical pathway - Important in executive functions & complex behavioural patterns.
What are the two families of dopamine receptors and which receptors fall into each of these families?
D1 family – D1 + D5 (Gs linked)
D2 family – D2, D3 + D4 (Gi linked)
Describe dopamine synthesis.
L-Tyrosine is converted by tyrosine hydroxylase to L-DOPA
L-DOPA is converted by DOPA decarboxylase to Dopamine
Is Parkinson’s disease more common in males or females?
Males – 4:1
What percentage of all cases of Parkinson’s disease is accounted for by genetic mutations?
5%
The rest are idiopathic
What are the possible causes of idiopathic Parkinson’s disease?
Possibly a combination of environmental, oxidative stress, altered protein metabolism and risk genes
What are the cardinal signs of Parkinson’ disease?
Resting tremor (pill-rolling tremor)
Rigidity (stiffness – limbs feel weak and heavy)
Bradykinesia (slowness of movement)
Postural instability
What are the ANS effects of parkinsons?
Olfactory deficits
Orthostatic hypotension
Constipation
What is the main area of the brain that is affected by Parkinson’s disease?
Substantia nigra
Describe the neuropathology of Parkinson’s disease.
Lewy bodies and Lewy neurites (composed of the same material but in different cellular locations) found in dopaminergic neurones
Strongly associated with neurodegeneration
What is the main biochemical change seen in Parkinson’s disease?
Marked reduction in the caudate nucleus/putamen dopamine content
What proportion of dopaminergic neurones of the nigrostriatal dopaminergic pathway must be lost before symptoms occur?
80-85% of dopaminergic neurones and 70% of striatal dopamine must be depleted before symptoms appear
What is the reason for this loss of neurones before symptoms appear?
There are compensatory mechanisms e.g. neurone overactivity and increase in dopamine receptors
What other type of drug has to be given with Levodopa in dopamine replacement therapy and why?
DOPA decarboxylase inhibitor
This prevents the conversion of L-DOPA to dopamine by peripheral DOPA decarboxylase
They dont cross the BBB so conversion of L-DOPA (Levodopa) occurs in the brain where it is needed
e.g. Carbidopa or Benserazide
What drug is also sometimes administered with levodopa?
A COMT inhibitor to increase the amount of levodopa in the brain
e.g. Entacapone or Tolcapone
What is the treatment for Parkinsons?
No disease modifying treatment, can only teat symptoms
- Dopamine replacement
- Dopamine receptor agonsits
- MAOb inhibitors
Explain what is used for dopamine replacement?
Levodopa (L-DOPA)
Rapidly converted to DA by DOPA decarboxylase (DOPA-D)
Can cross blood-brain barrier (BBB)
Explain the side effects of levodopa
Nausea and vomiting
Explain the chronic side effects of levodopa
Dykinesias - unknown cause
‘On-Off positive effects’ - possibly due to fluctuations in plasma L-DOPA and a loss in the neurons ability to store DA.
Give 2 examples of the classes of dopamine receptor agonsits
Ergot derived:
Bromocriptine
Pergolide
Non-ergot derived:
Ropinirole
Rotigotine
Which receptors do dopamine receptor agonsits act on?
D2 receptor
What are the benefits of dopamine agonists over L-DOPA?
Longer duration of action
Smoother and more sustained response
Actions independent of dopaminergic neurones
Incidence of dyskinesias is less
NOTE: L-DOPA is still the gold standard
Name two MAO inhibitors.
Selegiline (Deprenyl)
Rasagiline
What are the effects of benefits of using a MAOb inhibitor?
Selective for MAO-B (this predominates in dopaminergic areas of CNS)
Does NOT have the peripheral side effects of non-selective MAO inhibitors
Can be given in combination with Levodopa (reduce dose of Levodopa by 30-50%)
Delays the amount of time before Levodopa must be started to give the patient more years of treatmetn (extends available treatment from 7 years to 9 years)